Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
PFTs
Do you implement FEV3/FEV6 or FEF25-75 measurements in the evaluation of patients for small airways obstruction?
Related Questions
How do you mitigate the risk of inadverdent under or over diagnosis of COPD in certain populations with transition to race-neutral spirometry reference equations?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
When do you consider switching from another biologic to benralizumab in patients with severe eosinophilic asthma with a history of suboptimal response to previous biologic agents?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
What is your approach to addressing comorbidities that influence asthma severity?
Do you prescribe lower dose ICS for asthma to mitigate the risk of pneumonia in patients with a history of respiratory infections or compromised immune systems?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
What role might depemokimab play in the stepwise approach to asthma management, especially for patients who have previously failed other biologic therapies?
